<link rel="stylesheet" type="text/css" href="https://ubosquemoodle.unbosque.edu.co/theme/uebtheme/css/stylesUEB.css">
<script src="http://res.cloudinary.com/vsevolodts/raw/upload/v1503371762/timeit.min.js" type="text/javascript"></script>
<script src="http://cdnjs.cloudflare.com/ajax/libs/jquery-easing/1.3/jquery.easing.min.js" type="text/javascript"></script>
<link rel="stylesheet" href="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/EPOC-astrazeneca/dist/css/lightbox.min.css" />
<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/EPOC-astrazeneca/dist/js/lightbox-plus-jquery.min.js" type="text/javascript"></script>
<script src="https://code.jquery.com/jquery-latest.min.js" type="text/javascript"></script>
<script src="http://res.cloudinary.com/vsevolodts/raw/upload/v1503371762/timeit.min.js"></script>
<script src="http://cdnjs.cloudflare.com/ajax/libs/jquery-easing/1.3/jquery.easing.min.js"></script>
<!-- ================== script ================== -->
<script src="https://code.jquery.com/jquery-latest.min.js" type="text/javascript"></script>
<!-- ================== lightbox ================== -->
<!-- ================== animate scroll ================== -->
<link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/animate.css/3.5.1/animate.min.css">
<script type="text/javascript" src="https://cdnjs.cloudflare.com/ajax/libs/wow/1.1.2/wow.min.js"></script>
<!-- ================== fin animate scroll ================== -->
<!-- ================== css ================== -->
<link rel="stylesheet" href="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/EPOC-astrazeneca/css/styles.css" />
<link rel="stylesheet" type="text/css" href="../../css/styles.css">
<div class="curso-cc">
  <div class="container-fluid">
    <div class="row-fluid">
      <div class="content-cc">
        <div class="banner-home" id="banner-home"></div>
        <div id="menu"></div>
        <h2>Módulo 2 / <span>Epidemiología, diagnóstico y diagnóstico diferencial del Mieloma Múltiple</span></h2>
        <h3>5. Referencias</h3>
        <ol>
          <li>Swerdlow S, Campo E, Lee Harris N, Jaffe E. WHO Classification of Tumours of Hematopoietic and Lymphoid Tissues. Revised 4th Edition. Lyon: IARC; 2017. </li>
          <li>Andrade R, Chinchilla S, Echeverry C, Jaramillo R, Ordúz R. Primer consenso de expertos en diagnóstico de leucemias y linfomas en Colombia. PILAC; 2016. </li>
          <li>Demharter J, Müller P, Wagner T, Schlimok G, Haude K, Bohndorf K. Percutaneous core-needle biopsy of enlarged lymph nodes in the diagnosis and subclassification of malignant lymphomas. Eur Radiol. 2001;11(2):276-83. </li>
          <li>Demharter J, Neukirchen S, Wagner T, Schlimok G, Bohndorf K, Kirchhof K. [Do ultrasound-guided core needle biopsies of lymph nodes allow for subclassification of malignant lymphomas?]. ROFO Fortschr Geb Rontgenstr Nuklearmed. abril de 2007;179(4):396-400. </li>
          <li>Burke C, Thomas R, Inglis C, Baldwin A, Ramesar K, Grace R, et al. Ultrasound-guided core biopsy in the diagnosis of lymphoma of the head and neck. A 9 year experience. Br J Radiol. agosto de 2011;84(1004):727-32. </li>
          <li>Frederiksen JK, Sharma M, Casulo C, Burack WR. Systematic Review of the Effectiveness of Fine-Needle Aspiration and/or Core Needle Biopsy for Subclassifying Lymphoma. Arch Pathol Lab Med. febrero de 2015;139(2):245-51. </li>
          <li>the German Low-grade Lymphoma Study Group (GLSG), Johl A, Lengfelder E, Hiddemann W, Klapper W. Core needle biopsies and surgical excision biopsies in the diagnosis of lymphoma—experience at the Lymph Node Registry Kiel. Ann Hematol. agosto de 2016;95(8):1281-6. </li>
          <li>Wang Y, Li Q, Zhu L, Mao X, Zhang H, Huang L, et al. Cytogenetics with flow cytometry in lymph node/extranodal tissue biopsies is sensitive to assist the early diagnosis of suspected lymphomas. Ann Hematol. octubre de 2017;96(10):1673-80. </li>
          <li>Fend F. Clasical Hodgkin’s lymphoma and related lesions. En: Hematopatology. Second edition. Elsevier; 2017. p. 525-45. </li>
          <li>Hoppe R, editor. Hodgkin lymphoma. 2nd ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2007. 466 p. </li>
          <li>DeVita VT, Lawrence TS, Rosenberg SA. Lymphomas and leukemias [Internet]. 2016 [citado 17 de febrero de 2019]. Disponible en:  <a href="http://public.ebookcentral.proquest.com/choice/publicfullrecord.aspx?p=4786218" target="_blank">http://public.ebookcentral.proquest.com/choice/publicfullrecord.aspx?p=4786218</a></li>
          <li>Magrath I, editor. The lymphoid neoplasms. 3rd ed. London: Hodder Arnold; 2010. 1657 p. </li>
          <li>Küppers R, Engert A, Hansmann M-L. Hodgkin lymphoma. J Clin Invest. 1 de octubre de 2012;122(10):3439-47. </li>
          <li>Mathas S, Hartmann S, Küppers R. Hodgkin lymphoma: Pathology and biology. Semin Hematol. julio de 2016;53(3):139-47. </li>
          <li>Eichenauer DA, Engert A. Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management. 2017;5. </li>
          <li>Klimm B, Franklin J, Stein H, Eichenauer DA, Haverkamp H, Diehl V, et al. Lymphocyte-Depleted Classical Hodgkin’s Lymphoma: A Comprehensive Analysis From the German Hodgkin Study Group. J Clin Oncol. 10 de octubre de 2011;29(29):3914-20. </li>
          <li>Oluwasanjo A, Kartan S, Johnson W, Alpdogan O, Gru A, Mishra A, et al. Peripheral T-Cell Lymphoma, not Otherwise Specified (PTCL-NOS). En: Querfeld C, Zain J, Rosen ST, editores. T-Cell and NK-Cell Lymphomas [Internet]. Cham: Springer International Publishing; 2019 [citado 17 de febrero de 2019]. p. 83-98. Disponible en:  <a href="http://link.springer.com/10.1007/978-3-319-99716-2_4" target="_blank"> http://link.springer.com/10.1007/978-3-319-99716-2_4</a></li>
          <li>International T-Cell Lymphoma Project. International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes. J Clin Oncol. septiembre de 2008;26(25):4124-30. </li>
          <li>Federico M, Bellei M, Marcheselli L, Schwartz M, Manni M, Tarantino V, et al. Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network. Br J Haematol. junio de 2018;181(6):760-9. </li>
          <li>Ferry JA. Angioimmunoblastic T-cell Lymphoma: Adv Anat Pathol. septiembre de 2002;9(5):273-9. </li>
          <li>Jaffe ES, Arber DA, Campo E, Harris NL, Quintanilla-Martinez L, editores. Hematopathology. Second edition. Philadelphia, PA: Elsevier; 2017. 1199 p. </li>
          <li>Armitage JO. The aggressive peripheral T-cell lymphomas: 2017: ARMITAGE. Am J Hematol. julio de 2017;92(7):706-15. </li>
          <li>Willemze R, Cerroni L, Kempf W, Berti E, Facchetti F, Swerdlow SH, et al. The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas. Blood. 11 de enero de 2019;blood-2018-11-881268. </li>
          <li>Cerroni L. Skin lymphoma: the illustrated guide. Fourth edition. Chichester, West Sussex, UK: John Wiley & Sons, Ltd; 2014. </li>
          <li>Foss FM, Girardi M. Mycosis Fungoides and Sezary Syndrome. Hematol Oncol Clin North Am. abril de 2017;31(2):297-315. </li>
          <li>Scarisbrick JJ, Morris S. How big is your hand and should you use it to score skin in cutaneous T-cell lymphoma? Br J Dermatol. agosto de 2013;169(2):260-5. </li>
          <li>Pimpinelli N, Olsen EA, Santucci M, Vonderheid E, Haeffner AC, Stevens S, et al. Defining early mycosis fungoides. J Am Acad Dermatol. diciembre de 2005;53(6):1053-63. </li>
          <li>Vandergriff T, Nezafati KA, Susa J, Karai L, Sanguinetti A, Hynan LS, et al. Defining early mycosis fungoides: validation of a diagnostic algorithm proposed by the International Society for Cutaneous Lymphomas: Defining early mycosis fungoides. J Cutan Pathol. mayo de 2015;42(5):318-28. </li>
          <li>Mahévas T, Ram-Wolff C, Battistella M, Pennamen MDV, Rivet J, Brice P, et al. Dramatic response to brentuximab vedotin in refractory nontransformed CD30 - mycosis fungoides allowing allogeneic stem cell transplant and long-term complete remission. Br J Dermatol [Internet]. 1 de enero de 2019 [citado 20 de febrero de 2019]; Disponible en:    <a href="http://doi.wiley.com/10.1111/bjd.17254" target="_blank"> http://doi.wiley.com/10.1111/bjd.17254</a></li>
          <li>Goggins CA, Gocke MT, Jang S, DeSimone JA. Oral mycosis fungoides with CD30+ large cell transformation successfully treated with brentuximab vedotin. JAAD Case Rep. febrero de 2019;5(2):180-3. </li>
          <li>Campbell JJ, Clark RA, Watanabe R, Kupper TS. Sezary syndrome and mycosis fungoides arise from distinct T-cell subsets: a biologic rationale for their distinct clinical behaviors. Blood. 5 de agosto de 2010;116(5):767-71. </li>
          <li>Alfred A, Taylor PC, Dignan F, El-Ghariani K, Griffin J, Gennery AR, et al. The role of extracorporeal photopheresis in the management of cutaneous T-cell lymphoma, graft-versus-host disease and organ transplant rejection: a consensus statement update from the UK Photopheresis Society. Br J Haematol. abril de 2017;177(2):287-310. </li>
          <li>Chen C, Gu YD, Geskin LJ. A Review of Primary Cutaneous CD30+ Lymphoproliferative Disorders. Hematol Oncol Clin North Am. febrero de 2019;33(1):121-34. </li>
          <li>Woo DK, Jones CR, Vanoli-Storz MN, Kohler S, Reddy S, Advani R, et al. Prognostic Factors in Primary Cutaneous Anaplastic Large Cell Lymphoma: Characterization of Clinical Subset With Worse Outcome. Arch Dermatol [Internet]. 1 de junio de 2009 [citado 21 de febrero de 2019];145(6). Disponible en:   <a href="http://archderm.jamanetwork.com/article.aspx?doi=10.1001/archdermatol.2009.74" target="_blank">  http://archderm.jamanetwork.com/article.aspx?doi=10.1001/archdermatol.2009.74</a></li>
          <li>Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification. J Clin Oncol. 20 de septiembre de 2014;32(27):3059-67. </li>
          <li>Olsen E, Vonderheid E, Pimpinelli N, Willemze R, Kim Y, Knobler R, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 15 de septiembre de 2007;110(6):1713-22. </li>
          <li>Kim YH, Willemze R, Pimpinelli N, Whittaker S, Olsen EA, Ranki A, et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 15 de marzo de 2007;110(2):479-84.</li>
        </ol>
        <div class="progreso">
          <h2>Progreso módulo</h2>
          <div id="progreso100"></div>
        </div>
      </div>
    </div>
  </div>
  <div class="container-fluid">
    <div class="row-fluid wow fadeInUp material-modulo">
      <div id="material-mod-5"></div>
    </div>
  </div>
  <div class="container-fluid">
    <div class="row-fluid">
      <div class="span" id="footer-2"></div>
    </div>
  </div>
  <div class="container-fluid">
    <div class="row-fluid wow fadeInUp codigo-modulo">
      <p class="small">Modulo 5: CO/ONC/1902/0002c – Diagnóstico - Mieloma</p>
    </div>
  </div>
  <div class="container-fluid">
    <div class="row-fluid">
      <ul class="pager">
        <li class="previous"><a class="available" href="https://ubosquemoodle.unbosque.edu.co/mod/page/view.php?id=294388">Anterior</a></li>
        <li class="next"><a class="disabled" href="#">Siguiente</a></li>
      </ul>
    </div>
  </div>
</div><!-- ================== script ================== -->
<script src="../../Menu/menu.js" type="text/javascript"></script>
<script src="../../Menu/timeit.js"></script>
<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/EPOC-astrazeneca/Menu/menu.js" type="text/javascript"></script>
<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/EPOC-astrazeneca/Menu/timeit.js" type="text/javascript"></script>
<!-- ================== fin script ================== -->
<script src="jquery.min.js"></script>
<script src="https://ubosquemoodle.unbosque.edu.co/diseno/cursos/EPOC-astrazeneca/iframe-code/set-iframe-height-child.js"></script>
<script type="text/javascript">$(document).ready(function() {$("#single_1").fancybox({helpers: {title : {type : 'float'}}	});});</script>
<script type="text/javascript">$(".menu-toggle").click(function() {$("nav > ul").slideToggle( "700");$("nav > ul").css('display','flex');});</script>
<!-- ================== script animate scroll ================== -->
<script type="text/javascript">new WOW().init();</script>
<!-- ================== fin script animate scroll ================== -->
<script src="http://code.jquery.com/jquery.js"></script>
<script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/2.3.2/js/bootstrap.min.js"></script>